A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer (CCODG-NSCLC)
A Multi-Center and Randomized Control Trial of Cisplatin, Carboplatin, Oxaliplatin, Docetaxel and Gemcitabine Plus Surgery as Treatment for Relapsed and Refractory Non-Small Cell Lung Cancer
Sponsor: Jiangxi Provincial Cancer Hospital
This PHASE1 trial investigates Recurrent Non-small Cell Lung Cancer and is currently actively recruiting participants. Jiangxi Provincial Cancer Hospital leads this study, which shows 11 recorded versions since 2008 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
-
May 2024 — Jul 2024 [monthly]
Recruiting PHASE1
-
Jun 2022 — May 2024 [monthly]
Recruiting PHASE1
-
Jan 2021 — Jun 2022 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Recruiting PHASE1
-
May 2019 — Nov 2020 [monthly]
Recruiting PHASE1
-
Jun 2018 — May 2019 [monthly]
Recruiting PHASE1
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Mar 2018 — Apr 2018 [monthly]
Recruiting PHASE1
-
Jan 2017 — Mar 2018 [monthly]
Recruiting PHASE1
First recorded
Jan 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangxi Provincial Cancer Hospital
- Jilin University
- Shanghai 10th People's Hospital
- Shanghai Jiao Tong University School of Medicine
- Shanghai Tongji Hospital, Tongji University School of Medicine
For direct contact, visit the study record on ClinicalTrials.gov .